CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 18 and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). The positive vote was unanimous with 11 ACIP members recommending the booster.
“We thank the ACIP for this recommendation, which will provide individuals with another layer of protection against COVID-19 as we enter the winter months and as cases of COVID-19 and hospitalizations are increasing across the country”
Tweet this
“We thank the ACIP for this recommendation, which will provide individuals with another layer of protection against COVID-19 as we enter the winter months and as cases of COVID-19 and hospitalizations are increasing across the country,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This is another important step in our quest to address this pandemic with our mRNA vaccine.”
The ACIP is comprised of independent health experts. Today’s ACIP recommendation follows the FDA’s emergency use authorization of a booster dose. This ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human...
Read Full Story:
https://www.businesswire.com/news/home/20211119005733/en/U.S.-CDC-Advisory-Co...